Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishi...
June 27 2017 - 8:30AM
Business Wire
Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy
company, has been named to MIT Technology Review’s 2017 list of 50
Smartest Companies. To make the list, a company must exhibit
technological leadership and business acumen which sets them apart
from competitors. Kite was ranked #7 on this list for its
leadership in establishing the field of engineered cell therapy for
the treatment of cancer.
“The companies on the list combine a high level of technology
innovation with a business model that will help them make the most
of it,” said Nanette Byrnes, senior editor for business of MIT
Technology Review. “Public and private, large and small, based in
countries around the globe, this group of companies is creating new
opportunities and pouncing on them. These are the ones that
competitors must follow.”
The decades long journey of developing chimeric antigen receptor
(CAR) technology by institutions such as the National Cancer
Institute has seen tremendous advancement in just the last few
years. Beginning in late 2014, Kite was able to accelerate
development of engineered cell therapy and its lead CAR-T
candidate, axicabtagene ciloleucel. That effort led to the
presentation earlier this year of positive data from ZUMA-1, the
first pivotal CAR-T trial in patients with refractory aggressive
B-cell non-Hodgkin lymphoma (NHL). A Biological License Application
(BLA) for axicabtagene ciloleucel has been accepted by the FDA and,
if approved, Kite plans to commercially launch axicabtagene
ciloleucel in 2017.
“Kite is honored to be included and recognized as part of MIT
Technology Review’s 50 Smartest Companies List for our work in
establishing CAR-T therapy,” said Arie Belldegrun, MD, FACS,
Chairman, President and Chief Executive Officer of Kite. “This year
will be a transformative year across the industry for this
paradigm-changing technology, which includes the potential approval
by the FDA of axicabtagene ciloleucel. At Kite, we utilized the
years of pioneering research from our academic collaborators and
assembled a team of industry experts to advance engineered cell
therapies from early research to full commercialization to address
an important unmet clinical need.”
The list is included in MIT Technology Review’s annual business
issue, which is available online now and on newsstands worldwide on
July 4, 2017.
About MIT Technology Review
Founded at the Massachusetts Institute of Technology in 1899,
MIT Technology Review is a digitally oriented independent media
company whose analysis, features, reviews, interviews, and live
events explain the commercial, social, and political impact of new
technologies. MIT Technology Review readers are curious technology
enthusiasts—a global audience of business and thought leaders,
innovators and early adopters, entrepreneurs and investors. Every
day, MIT Technology Review provides an authoritative filter for the
flood of information about technology. The company is the first to
report on a broad range of new technologies, informing its
audiences about how important breakthroughs will impact their
careers and their lives. Subscribe. Follow MIT Technology Review:
Twitter, Facebook, LinkedIn, Google+, Instagram.
About Kite
Kite is a biopharmaceutical company engaged in the development
of innovative cancer immunotherapies with a goal of providing
rapid, long-term durable response and eliminating the burden of
chronic care. The company is focused on chimeric antigen receptor
(CAR) and T cell receptor (TCR) engineered cell therapies designed
to empower the immune system's ability to recognize and kill
tumors. Kite is based in Santa Monica, CA. For more
information on Kite, please visit www.kitepharma.com. Sign up
to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the timing and ability of obtaining regulatory
approval and commercially launching axicabtagene ciloleucel and the
ability to advance engineered cell therapies. Various factors may
cause differences between Kite's expectations and actual results as
discussed in greater detail in Kite's filings with the Securities
and Exchange Commission, including without limitation in its Form
10-Q for the quarter ended March 31, 2017. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Kite assumes no obligation to update
the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170627005518/en/
KiteChristine CassianoSVP, Corporate Communications &
Investor Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Sep 2024 to Oct 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Oct 2023 to Oct 2024